Reversed association between aldosterone and mortality in hemodialysis patients: Role of volume overload

Steroids

Volumn 111, Issue , 2016, Pages 60-62

  Hung, Szu Chun ^a   Tarng, Der Cherng ^b,c  

^a TZU CHI UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Aldosterone; Cardiovascular disease; Hemodialysis; Mortality; Volume overload

Indexed keywords

ALDOSTERONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALDOSTERONE BLOOD LEVEL; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; END STAGE RENAL DISEASE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERALDOSTERONEMIA; HYPERVOLEMIA; KIDNEY FIBROSIS; MORTALITY; NONHUMAN; REVIEW; SODIUM RESTRICTION; WATER DEPRIVATION; ADVERSE EFFECTS; ANIMAL; KIDNEY FAILURE, CHRONIC; METABOLISM; WATER-ELECTROLYTE IMBALANCE;

ALDOSTERONE; ANIMALS; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; WATER-ELECTROLYTE IMBALANCE;

EID: 84975477029     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2016.01.012     Document Type: Review

References (30)

1. P. Rossignol, J. Ménard, R. Fay, F. Gustafsson, B. Pitt, and F. Zannad Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects: Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy J. Am. Coll. Cardiol. 58 2011 1958 1966
2. R.N. Foley, P.S. Parfrey, and M.J. Sarnak Clinical epidemiology of cardiovascular disease in chronic kidney disease Am. J. Kidney Dis. 32 1998 112 119
3. R. Hene, P. Boer, H. Koomans, and E. Mees Plasma aldosterone concentrations in chronic renal disease Kidney Int. 21 1982 98 101
4. C.J. Diskin, T.J. Stokes, L.M. Dansby, T.B. Carter, and L. Radcliff The clinical significance of aldosterone in ESRD: Part II Nephrol. Dial. Transplant. 19 2004 1331 1332
5. K. Kohagura, Y. Higashiuesato, T. Ishiki, S. Yoshi, Y. Ohya, K. Iseki, and S. Takishita Plasma aldosterone in hypertensive patients on chronic hemodialysis: distribution, determinants and impact on survival Hypertens. Res. 29 2006 597 604
6. A. Tomaschitz, S. Pilz, E. Ritz, A. Meinitzer, B.O. Boehm, and W. März Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study Eur. Heart J. 31 2010 1237 1247
7. A. Tomaschitz, S. Pilz, E. Ritz, T. Grammer, C. Drechsler, B.O. Boehm, and W. März Association of plasma aldosterone with cardiovascular mortality in patients with low estimated GFR: the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study Am. J. Kidney Dis. 57 2011 403 414
8. S.C. Hung, K.L. Kuo, C.H. Peng, C.H. Wu, Y.C. Lien, Y.C. Wang, and D.C. Tarng Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease Kidney Int. 85 2014 703 709
9. S.C. Hung, K.L. Kuo, C.H. Peng, C.H. Wu, Y.C. Wang, and D.C. Tarng Association of fluid retention with anemia and clinical outcomes among patients with chronic kidney disease J. Am. Heart Assoc. 4 2015 e001480
10. S.C. Hung, Y.S. Lai, K.L. Kuo, and D.C. Tarng Volume overload and adverse outcomes in chronic kidney disease: clinical observational and animal studies J. Am. Heart Assoc. 4 2015 e001918
11. P.J. Klemmer, and A.S. Bomback Extracellular volume and aldosterone interaction in chronic kidney disease Blood Purif. 27 2009 92 98
12. S.C. Hung, Y.P. Lin, H.L. Huang, H.F. Pu, and D.C. Tarng Aldosterone and mortality in hemodialysis patients: role of volume overload PLoS One 8 2013 e57511
13. T.H. Hostetter, and H.N. Ibrahim Aldosterone in chronic kidney and cardiac disease J. Am. Soc. Nephrol. 14 2003 2395 2401
14. K.T. Weber, and C.G. Brilla Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system Circulation 83 1991 1849 1865
15. G. Guder, J. Bauersachs, S. Frantz, D. Weismann, B. Allolio, G. Ertl, C.E. Angermann, and S. Störk Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure Circulation 115 2007 1754 1761
16. F. Beygui, J.P. Collet, J.J. Benoliel, N. Vignolles, R. Dumaine, O. Barthélémy, and G. Montalescot High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction Circulation 114 2006 2604 2610
17. N.C. Edwards, R.P. Steeds, P.M. Stewart, C.J. Ferro, and J.N. Townend Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial J. Am. Coll. Cardiol. 54 2009 505 512
18. D. Green, P.R. Roberts, D.I. New, and P.A. Kalra Sudden cardiac death in hemodialysis patients: an in-depth review Am. J. Kidney Dis. 57 2011 921 929
19. T. Berl, F.H. Katz, W.L. Henrich, A. de Torrente, and R.W. Schrier Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure Kidney Int. 14 1978 228 235
20. D. Ratge, R. Augustin, and H. Wisser Catecholamines, renin, aldosterone and arterial pressure in patients on chronic hemodialysis treatment Int. J. Artif. Organs 6 1983 255 260
21. N. McLaughlin, T.W. Gehr, and D.A. Sica Aldosterone-receptor antagonism and end-stage renal disease Curr. Hypertens. Rep. 6 2004 327 330
22. A. Covic, P. Gusbeth-Tatomir, and D.J. Goldsmith Is it time for spironolactone therapy in dialysis patients? Nephrol. Dial. Transplant. 21 2006 854 858
23. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Perez, J. Palensky, and J. Wittes The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators N. Engl. J. Med. 341 1999 709 717
24. B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, B. Roniker, R. Bittman, S. Hurley, J. Kleiman, and M. Gatlin Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N. Engl. J. Med. 348 2003 1309 1321
25. G.M. London, B. Pannier, E. Vicaut, A.P. Guérin, S.J. Marchais, M.E. Safar, and J.L. Cuche Antihypertensive effects and arterial haemodynamic alterations during angiotensin converting enzyme inhibition J. Hypertens. 14 1996 1139 1146
26. G.M. London, B. Pannier, A.P. Guerin, J. Blacher, S.J. Marchais, B. Darne, F. Metivier, H. Adda, and M.E. Safar Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study J. Am. Soc. Nephrol. 12 2001 2759 2767
27. J. Blacher, A.P. Guerin, B. Pannier, S.J. Marchais, M.E. Safar, and G.M. London Impact of aortic stiffness on survival in end-stage renal disease Circulation 99 1999 2434 2439
28. J.L. Tycho Vuurmans, W.H. Boer, W.J. Bos, P.J. Blankestijn, and H.A. Koomans Contribution of volume overload and angiotensin II to the increased pulse wave velocity of hemodialysis patients J. Am. Soc. Nephrol. 13 2002 177 183
29. S. Vegter, A. Perna, M.J. Postma, G. Navis, G. Remuzzi, and P. Ruggenenti Sodium intake, ACE inhibition, and progression to ESRD J. Am. Soc. Nephrol. 23 2012 165 173
30. M.C. Slagman, F. Waanders, M.H. Hemmelder, A.J. Woittiez, W.M. Janssen, H.J. Lambers Heerspink, G. Navis, and G.D. Laverman Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial BMJ 343 2011 d4366